<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pediatric acute kidney injury: Indications, timing, and choice of modality for kidney replacement therapy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pediatric acute kidney injury: Indications, timing, and choice of modality for kidney replacement therapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pediatric acute kidney injury: Indications, timing, and choice of modality for kidney replacement therapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melissa Muff-Luett, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tej K Mattoo, MD, DCH, FRCP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 22, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H4746388"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Critically ill children with acute kidney injury (AKI) are at greater risk for mortality than those without AKI due to associated complications, including symptomatic uremia, metabolic and electrolyte abnormalities, and fluid overload. The management of children with AKI is supportive, with kidney replacement therapy (KRT) indicated in patients with severe kidney injury. (See  <a class="medical medical_review" href="/d/html/6090.html" rel="external">"Prevention and management of acute kidney injury (acute renal failure) in children", section on 'Management of acute kidney injury'</a>.)</p><p>The indications, timing, and modalities for KRT for children with AKI will be reviewed here. KRT in adults with AKI is discussed separately. (See  <a class="medical medical_review" href="/d/html/1927.html" rel="external">"Kidney replacement therapy (dialysis) in acute kidney injury in adults: Indications, timing, and dialysis dose"</a>.)</p><p class="headingAnchor" id="H1275824769"><span class="h1">DEFINITIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute kidney injury (AKI)</strong> is characterized by a sudden decrease in the ability of the kidneys to maintain adequate electrolyte, acid-base, and fluid homeostasis along with a reduction in glomerular filtration rate [<a href="#rid1">1-3</a>]. Clinically, AKI is manifested by increases in nitrogenous waste products (blood urea nitrogen [BUN]) and serum creatinine (SCr) and, in many cases, a concomitant reduction in urine output (less than 0.5 to 1 mL/kg per hour) that may be refractory to diuretic therapy [<a href="#rid1">1-3</a>]. In severe AKI, a change in urine output may be identified before any change in serum creatinine; thus it has been proposed that both urine output and creatinine must be used to identify and stage AKI [<a href="#rid4">4,5</a>].</p><p></p><p class="bulletIndent1">Several published criteria are used clinically to manage pediatric AKI [<a href="#rid5">5,6</a>]. This topic uses the Kidney Disease Improving Global Outcomes definition and staging based on consensus of pediatric nephrology experts following a systematic review of the literature  (<a class="graphic graphic_table graphicRef93722" href="/d/graphic/93722.html" rel="external">table 1</a>). Other definitions used to guide clinical care include pRIFLE (Pediatric Risk, Injury, Failure, Loss, End Stage Renal Disease)  (<a class="graphic graphic_table graphicRef68721" href="/d/graphic/68721.html" rel="external">table 2</a>) and Acute Kidney Injury Network and are discussed separately. (See  <a class="medical medical_review" href="/d/html/6126.html" rel="external">"Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis", section on 'Definition'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney replacement therapy (KRT)</strong> is treatment that replaces the normal blood-filtering function of the kidneys. Several different modalities of KRT are used in children with AKI, including intermittent hemodialysis (HD), peritoneal dialysis, continuous KRT therapy (ie, continuous venovenous HD, continuous venovenous hemofiltration, continuous venovenous hemodiafiltration) and modified aquapheresis. (See <a class="local">'Modality'</a> below.)</p><p></p><p class="headingAnchor" id="H2562893005"><span class="h1">ACUTE KIDNEY INJURY AND MORTALITY: POTENTIAL ROLE OF KIDNEY REPLACEMENT THERAPY</span><span class="headingEndMark"> — </span>AKI and fluid overload are associated with greater morbidity and mortality in pediatric patients [<a href="#rid5">5,7-9</a>]. Mortality is highest in critically ill children, especially infants and those with multiorgan failure and significant fluid overload [<a href="#rid5">5,7,9-16</a>]. Kidney replacement therapy (KRT) prevents and corrects the adverse and potentially life-threatening complications of AKI including symptomatic uremia, metabolic and electrolyte imbalance, and severe fluid overload. Early initiation and effective administration of KRT in AKI is generally believed to improve survival in critically ill pediatric patients [<a href="#rid17">17</a>]. Nevertheless, there continues to be a lack of robust evidence-based guidelines regarding the indications for and timing of initiation of KRT in children, as well as the most appropriate KRT modality for pediatric use in various settings.</p><p class="headingAnchor" id="H1712461274"><span class="h1">INDICATION AND TIMING FOR KIDNEY REPLACEMENT THERAPY</span><span class="headingEndMark"> — </span>The decision to begin KRT is based on the severity and complications of AKI and the urgency of the clinical setting.</p><p class="headingAnchor" id="H1406959811"><span class="h2">Urgent indications</span><span class="headingEndMark"> — </span>Urgent indications include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Clinically significant fluid overload with evidence of escalating ventilatory support due to pulmonary edema and/or congestive cardiac failure, which is unresponsive to diuretic therapy and fluid restriction (typically seen in patients with &gt;15 percent fluid overload). (See <a class="local">'Fluid overload'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Presence of uremic complications such as pericarditis, uremic encephalopathy or unexplained change in mental status, and bleeding. (See  <a class="medical medical_review" href="/d/html/1661.html" rel="external">"Acute toxic-metabolic encephalopathy in adults", section on 'Uremic encephalopathy'</a> and  <a class="medical medical_review" href="/d/html/1947.html" rel="external">"Uremic platelet dysfunction"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Life-threatening metabolic derangements that are refractory to medical management:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Severe persistent hyperkalemia – Values typically &gt;6.5 mEq/L that are refractory to medical management or whenever there are associated electrocardiographic changes. (See  <a class="medical medical_review" href="/d/html/14274.html" rel="external">"Causes, clinical manifestations, diagnosis, and evaluation of hyperkalemia in children", section on 'Symptomatic patients'</a> and  <a class="medical medical_review" href="/d/html/14274.html" rel="external">"Causes, clinical manifestations, diagnosis, and evaluation of hyperkalemia in children", section on 'Cardiac conduction abnormalities'</a> and  <a class="medical medical_review" href="/d/html/85908.html" rel="external">"Management of hyperkalemia in children", section on 'Dialysis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Severe metabolic acidosis (pH &lt;7.1) refractory to medical therapy. (See  <a class="medical medical_review" href="/d/html/6100.html" rel="external">"Approach to the child with metabolic acidosis", section on 'Acute metabolic acidosis'</a> and  <a class="medical medical_review" href="/d/html/6100.html" rel="external">"Approach to the child with metabolic acidosis", section on 'Kidney replacement therapy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Severe persistent hyponatremia is a rare indication for KRT but mainly when associated with fluid overload.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Removal of toxins or drugs, which are dialyzable, including alcohols, <a class="drug drug_pediatric" data-topicid="12559" href="/d/drug information/12559.html" rel="external">lithium</a>, salicylates, and other drugs. (See  <a class="medical medical_review" href="/d/html/6487.html" rel="external">"Ethanol intoxication in children: Clinical features, evaluation, and management", section on 'Extracorporeal removal'</a> and  <a class="medical medical_review" href="/d/html/320.html" rel="external">"Lithium poisoning", section on 'Role of extracorporeal removal'</a> and  <a class="medical medical_review" href="/d/html/140354.html" rel="external">"Salicylate (aspirin) poisoning: Management", section on 'Indications for hemodialysis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other metabolic derangements including tumor lysis syndrome and hyperammonemia. (See  <a class="medical medical_review" href="/d/html/325.html" rel="external">"Enhanced elimination of poisons", section on 'Extracorporeal removal'</a> and  <a class="medical medical_review" href="/d/html/17050.html" rel="external">"Tumor lysis syndrome: Prevention and treatment", section on 'Indications for renal replacement therapy'</a> and  <a class="medical medical_review" href="/d/html/2923.html" rel="external">"Urea cycle disorders: Management", section on 'Hemodialysis'</a>.)</p><p></p><p class="headingAnchor" id="H1329404404"><span class="h2">Nonurgent indications</span><span class="headingEndMark"> — </span>For some patients with severe AKI but without one of the conditions listed above, dialysis may be warranted to prevent worsening complications and/or further deterioration of the patient's clinical status. In these cases, the decision to initiate KRT is based primarily on the judgement of clinicians in evaluating the level of impairment, patient factors (age/size, illness acuity, comorbidities, and ongoing needs), and organizational resources including availability of necessary equipment and trained, experienced staff. Nonurgent indications include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potential risk for clinically significant fluid overload</strong> – For patients with:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Reduced or fixed urine output (ie, oligoanuria), with high-volume requirement for administration of nutrition, medications, and/or blood products with evidence of continued deterioration of renal function.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Impending fluid overload with tachycardia, hypertension, or escalating ventilatory requirement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory electrolytes and acid-base disturbances</strong> – Deteriorating electrolyte and acid-base anomalies not responding to supportive management (eg, refractory severe hyperkalemia) but not yet meeting life-threatening values (noted above).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elevated blood urea nitrogen (BUN)</strong> – In our practice, we consider the use of KRT when the BUN reaches a level between 80 and 100 mg/dL in the context of oliguria without response to diuretics, worsening electrolyte abnormalities, and nutritional need. However, data from adult studies suggest that early initiation of KRT is not beneficial as the use of BUN as an indicator for KRT is limited by several nonrenal factors that affect BUN measurements. These include gastrointestinal bleeding, steroid use, diuretic use, catabolism, and nutritional intake. (See  <a class="medical medical_review" href="/d/html/1927.html" rel="external">"Kidney replacement therapy (dialysis) in acute kidney injury in adults: Indications, timing, and dialysis dose", section on 'Timing of elective initiation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum creatinine (SCr)</strong> – Elevated serum creatinine by itself is not an indication for KRT. Increases in SCr often occur late in the course of AKI, and, thus, SCr is an imperfect marker to determine the appropriate timing of KRT [<a href="#rid18">18,19</a>]. SCr is also affected by muscle mass that varies according to the size, nutritional status, and underlying medical comorbidities of the child. Given the limitations associated with serum creatinine as a kidney function biomarker, decisions regarding initiation of KRT should take into account the multiple patient factors and not be based solely on changes in SCr or a cutoff SCr level.</p><p></p><p class="headingAnchor" id="H1000926264"><span class="h2">Evidence for kidney replacement therapy initiation and timing</span><span class="headingEndMark"> — </span>In children, there are sufficient data to provide guidelines to initiate KRT for fluid overload. However, data remain inadequate to support evidence-based guidelines for quantifiable values for uremia and metabolic disturbances. Nevertheless, most pediatric intensivists and nephrologists, including the authors, advocate for earlier implementation of KRT to avoid these late manifestations of AKI.</p><p class="headingAnchor" id="H2681152467"><span class="h3">Fluid overload</span><span class="headingEndMark"> — </span>Fluid overload is associated with increased mortality, increased length of mechanical ventilation for mechanically ventilated children, increased organ dysfunction, and prolonged intensive care unit and hospital stay when controlled for severity of illness in both single center and multicenter pediatric studies [<a href="#rid9">9,20-22</a>]. Observational data suggest that early initiation of KRT is beneficial in children with multiorgan dysfunction and fluid overload [<a href="#rid23">23</a>].</p><p>Based on these findings, the American College of Critical Care Medicine Clinical Guidelines for Hemodynamic Support of Neonates and Children with Septic Shock suggest that KRT be considered in pediatric patients with septic shock at risk for worsening significant fluid overload [<a href="#rid24">24</a>]. Once hemodynamic stability is achieved, diuretics or KRT can be used to remove fluid in patients who are &gt;10 percent fluid overloaded and are unable to maintain fluid balance with their native urine output and/or extrarenal losses. The patient's fluid status is evaluated by determining the percent fluid overload (FO) using the following equation:</p><div class="formulaContainer"><div class="formula"><p class="bulletIndent1">Percent FO at KRT initiation = [Fluid in (liters) – Fluid out (liters)]/admission weight (kg) × 100</p></div></div><p></p><p class="bulletIndent1"><strong>or</strong></p><p></p><div class="formulaContainer"><div class="formula"><p class="bulletIndent1">Percent FO at KRT initiation = [Current weight (kg) – Admission weight (kg)]/admission weight (kg) × 100</p></div></div><p></p><p>KRT also may be used to maintain the fluid status of critically ill children who remain oliguric, but require high volumes of intravenous fluids, including parenteral nutrition and medications and/or blood products. In this setting, KRT is not used to remove fluid but to prevent further fluid overload, which may lead to worsening respiratory status and cardiac function. Once the patient has achieved a satisfactory level of hemodynamic stability, the process of fluid removal can commence.</p><p class="headingAnchor" id="H4225306909"><span class="h3">Severe acute kidney injury</span><span class="headingEndMark"> — </span>Although data from adult studies have been inconclusive about the benefits of early KRT, we recommend elective initiation of KRT in pediatric patients with AKI when their renal injury is severe or unlikely to quickly resolve. The definitions and staging criteria of AKI are based on the degree of glomerular filtration rate reduction or change in serum creatinine (SCr) in addition to the urine output. However, as stated previously SCr is not the ideal biomarker for renal injury and even with AKI severity staging, the likely duration of AKI is difficult to predict. (See  <a class="medical medical_review" href="/d/html/6126.html" rel="external">"Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis", section on 'Serum creatinine'</a>.)</p><p>Several investigational tools are being studied to see if they can predict the severity of AKI in children and whether KRT should be initiated. However, these tools have not been conclusively validated in the clinical setting and as a result are not used routinely in managing pediatric AKI.</p><p class="bulletIndent1"><span class="glyph">●</span>Novel biomarkers, such as neutrophil gelatinase-associated lipocalin, insulin-like growth factor-binding protein 7, tissue inhibitor of metalloproteinases, kidney injury molecule-1, and interleukin 18 show promise in both their diagnostic and prognostic utility in the setting of AKI and may allow for early intervention prior to the onset of SCr rise, severe metabolic derangements, and fluid overload. These biomarkers and their role in predicting AKI are discussed separately [<a href="#rid25">25-29</a>]. (See  <a class="medical medical_review" href="/d/html/6126.html" rel="external">"Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis", section on 'Biomarkers of acute kidney injury'</a> and  <a class="medical medical_review" href="/d/html/85837.html" rel="external">"Investigational biomarkers and the evaluation of acute kidney injury", section on 'Diagnostic biomarkers'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13329" href="/d/drug information/13329.html" rel="external">Furosemide</a> stress test – Furosemide stress test, which assesses urine output after a weight-based dose of furosemide, has been reported to predict progression of AKI in both adults and children. In one study of 166 children who underwent cardiac surgery, the furosemide stress test was predicative of AKI with lower mean urine flow rate for patients with AKI compared with those without AKI at two hours (2.9 versus 5 mL/kg/hour) and at six hours (2.4 versus 4 mL/kg/hour) [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/d/html/85837.html" rel="external">"Investigational biomarkers and the evaluation of acute kidney injury", section on 'Furosemide stress test'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Combination of clinical factors (renal angina) – The use of a collection of clinical risk factors and signs of renal disease has been proposed as a method to identify patients most at risk for developing AKI, analogous to assessing myocardial infarction [<a href="#rid31">31</a>]. The risk of AKI (referred to as renal angina) would be based on the presence of established risk factors (eg, mechanical ventilation, history of cardiopulmonary bypass, bone marrow transplantation) and evidence of renal disease (fluid overload and changes in serum creatinine) [<a href="#rid32">32</a>]. The proposed renal angina criteria stratify patients into moderate-risk, high-risk, and very high-risk patients according to their underlying clinical condition. For each level of preexisting risk factors, there is a threshold of evidence of injury that a patient must meet to be considered to have renal angina  (<a class="graphic graphic_table graphicRef87768" href="/d/graphic/87768.html" rel="external">table 3</a>) [<a href="#rid32">32-36</a>].</p><p></p><p class="headingAnchor" id="H4746438"><span class="h1">MODALITY</span></p><p class="headingAnchor" id="H1578329631"><span class="h2">Available pediatric modalities</span><span class="headingEndMark"> — </span>The following modalities are available for the provision of KRT in the pediatric patient with AKI [<a href="#rid37">37-39</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Peritoneal dialysis (PD)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intermittent hemodialysis (HD)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Continuous kidney replacement therapies (CKRT), including:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Continuous venovenous hemodialysis (CVVHD)</p><p class="bulletIndent2"><span class="glyph">•</span>Continuous venovenous hemofiltration (CVVH)</p><p class="bulletIndent2"><span class="glyph">•</span>Continuous venovenous hemodiafiltration (CVVHDF)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prolonged intermittent kidney replacement therapy (PIKRT)</p><p></p><p class="headingAnchor" id="H2708126837"><span class="h2">Factors in modality selection</span><span class="headingEndMark"> — </span>All dialysis modalities can remove fluid and clear solutes. For the pediatric patients with AKI, selection of modality is typically based upon local expertise and availability of staff and equipment. However, in selected patients, other factors may need to be considered.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Size of the patient</strong> – This is a major consideration for dialysis modality selection as HD and CKRT may not be feasible in infants and small children &lt;15 kg in weight. Most CKRT machines and hemodialysis machines used in the United States are only approved for patients weighing more than 15 or 20 kg. As a result, machines must be used off-label to dialyze patients who fall below this cutoff. In addition, the extracorporeal volume of these circuits typically exceeds 10 percent of the blood volume of small patients &lt;10 to 120 kg. For these children, packed red blood cells are required to prime the extracorporeal circuit to prevent hemodynamic instability leading to exposure to donated blood [<a href="#rid40">40</a>]. Smaller dialyzers and extracorporeal circuits have been developed but are not universally available. As a result, PD remains the most common modality used for infants and small children who require KRT. (See  <a class="medical medical_review" href="/d/html/14562.html" rel="external">"Hemodialysis for children with chronic kidney disease", section on 'Dialyzer'</a> and  <a class="medical medical_review" href="/d/html/14562.html" rel="external">"Hemodialysis for children with chronic kidney disease", section on 'Extracorporeal circuit'</a> and  <a class="medical medical_review" href="/d/html/14562.html" rel="external">"Hemodialysis for children with chronic kidney disease", section on 'Small infants'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dialysis access</strong> – Hemodialysis and CKRT require placement of a large-bore dual lumen central catheter, which is often not an option in small children or infants or those with compromised vasculature.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemodynamic instability</strong> – Intermittent HD may be difficult to perform in hemodynamically unstable patients. In these patients, CKRT or PD allow for more gradual and sustained solute and fluid removal and less perturbations on the intravascular circulation than intermittent HD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abdominal or diaphragmatic pathology</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Abdominal defects may preclude the use of PD due to changes in clearance and filtration across a compromised peritoneal membrane</p><p class="bulletIndent2"><span class="glyph">•</span>Leakage of peritoneal solution used in dialysis may occur in patients with diaphragmatic defects</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anticipated duration of KRT</strong> – It is important to consider the likely length of KRT. For example, if a child is likely to require chronic dialysis and is a candidate for home therapy, PD might be the preferred initial selected mode of dialysis as it may facilitate transition to chronic KRT.</p><p></p><p class="headingAnchor" id="H2272661455"><span class="h2">Kidney replacement therapy modalities and clinical considerations</span><span class="headingEndMark"> — </span>Regardless of the modality choice, initiating KRT in a critically ill child requires collaboration among the pediatric nephrologists, intensivists, and other subspecialists. Early discussion and planning will facilitate the process and allow for more rapid intervention, thereby improving survival outcomes and reducing morbidity. All acute dialysis programs can be monitored and assessed through quality improvement programs with specific metrics and outcome indicators [<a href="#rid41">41</a>]. Quality improvement goals have been outlined for adult programs and similar quality improvement programs are now recommended in pediatric programs.</p><p>The following sections describe the use of available KRT modalities in pediatrics, including their relative advantages and disadvantages.</p><p class="headingAnchor" id="H4746452"><span class="h3">Peritoneal dialysis</span><span class="headingEndMark"> — </span>PD provides gradual, continuous solute and water clearance through diffusion and ultrafiltration, although the ability to separate these components is limited with this modality.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>General availability</strong> – Many centers have a relatively greater experience and comfort level using PD in pediatric patients compared with the other modalities. PD historically has provided effective therapy for the management of pediatric AKI and continues to provide reasonably cost-effective, efficient therapy. PD is widely available in resource-limited countries because it requires less technological expertise, as it does not require vascular access, less resource allocation, and is more cost effective than CKRT or HD. PD is critical in the treatment for any child with AKI especially in facilities where pediatric HD and CKRT are unavailable [<a href="#rid42">42,43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Access</strong> – PD does not require vascular access and thus allows critically ill patients to be dialyzed with preservation of vasculature for patients who may require chronic dialysis in the future. Access for PD can be quickly and safely obtained, even in hemodynamically unstable patients, thus allowing for the rapid institution of therapy. Typical access includes Tenckhoff catheters, usually placed in the operating room by pediatric surgeons, or acute PD or adapted PD catheters placed at the bedside percutaneously by experienced clinicians in patients unable to tolerate a surgical placement [<a href="#rid44">44,45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Components of the PD prescription</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dialysate composition</strong> – The composition of dextrose-based peritoneal dialysate solutions available in the United States includes sodium (132 mEq/L), magnesium (0.5 mEq/L), chloride (95 mEq/L), lactate for a bicarbonate source (40 mEq/L), and two different concentrations of calcium (2.5 and 3.5 mEq/L). Modifications customized to the needs of individual patients can be prepared by hospital pharmacies [<a href="#rid46">46,47</a>], although this does increases the risk of prescription errors or introduction of contaminants [<a href="#rid48">48</a>]. The most common supplementation is the addition of sodium to increase the standard composition of 130 mEq/L, typically in hyponatremic or hypotensive infants. Potassium or phosphate which are not included in standard PD formulations may also be required at times. In addition, bicarbonate may be used in patients with hepatic dysfunction who are unable to metabolize lactate.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Dextrose – Three different dextrose concentrations are available commercially in the United States: 1.5, 2.5, and 4.25% solutions with respective osmolalities of 346, 396, and 485 mOsm/L. The dextrose used in PD dialysate can provide an extra source of carbohydrate nutrition and calories [<a href="#rid47">47,49</a>], but may also lead to hyperglycemia necessitating insulin correction [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Heparin – Heparin is added to the dialysate when fibrin is present in the dialysate or during episodes of peritonitis given the possible antiangiogenic and anti-inflammatory properties [<a href="#rid51">51</a>]. When adding heparin we use the Pediatric International Society for Peritoneal Dialysis guidelines that suggest administrating intraperitoneal heparin at 500 to 1000 units per L until complete resolution of the cloudy effluent to prevent occlusion of the catheter [<a href="#rid52">52</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Exchange volume</strong> – The recommended initial exchange volume in acute pediatric PD is low (10 mL/kg) in order to minimize abdominal pressure that may cause dialysate leakage around the catheter. The volume can be slowly increased to a maximum of 35 to 40 mL/kg. As volume increases, the number of exchanges per day often can be decreased. Strict fluid balance is particularly critical in small children and infants and the use of buretrols allows for precise measurements of in- and outflow when operating a manual and gravity-based system used for these small patients [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dwell time</strong> – The time allowed for exchange of molecules and fluid is often short in pediatric patients. Initial standard dwell time is between 40 and 60 minutes, which is then adjusted based on the patient's fluid status, rate of ultrafiltration (fluid removal), and clinical course. Shorter dwell times can be utilized to increase ultrafiltration (fluid removal), but this may reduce clearance.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Number of daily exchanges</strong> – Number of exchanges per 24 hours depends on the duration of time required for the inflow, dwell, and outflow of dialysate for each exchange. Typically, on initiation, acute PD runs over the entire 24-hour day but, as the exchange volume is increased or the patient is stabilized, the amount of time on dialysis can be reduced.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specific clinical settings</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Multiorgan failure</strong> – Retrospective pediatric data show that PD can be performed successfully in the setting of multisystem organ failure, including cardiovascular instability requiring vasopressor support [<a href="#rid54">54,55</a>]. However, the ability to provide adequate dosing of dialysis in the AKI setting is problematic when using PD in the most critically ill patients. These patients, who may have severe fluid overload, lactic acidosis, and hypotension, require precise fluid balance with controlled ultrafiltration, but may not have adequate blood flow (cardiac output) to the peritoneum to allow for efficient solute and fluid removal. Pressor agents may alter peritoneal blood flow in septic patients, further diminishing these processes. Thus, in patients with sepsis-induced AKI the beneficial aspects of slow solute clearance and ultrafiltration provided by PD also limit its effectiveness. Patients with preload-dependent cardiac physiology may become unstable with filling and draining [<a href="#rid54">54,56</a>], necessitating the use of tidal PD prescriptions or an alternative modality such as CKRT. Patients with pulmonary compromise may worsen with increased abdominal dialysate volumes that may prevent full diaphragmatic excursion.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other settings</strong> – PD can be used to support patients with ventriculoperitoneal shunts, prune-belly syndrome, abdominal surgeries, and ventilation via the high-frequency oscillator, though these situations may present some technical challenges for catheter placement (eg, thin abdominal wall in patients with prune-belly syndrome) and come with higher risk of catheter malfunctions [<a href="#rid57">57</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contraindications</strong> – PD is absolutely contraindicated in patients with diaphragmatic defects due to leakage of peritoneal fluid into the pleural cavity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> – Complications of PD include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Peritonitis – The risk of peritonitis increases when using a PD catheter acutely due to the risk of dialysate leak and thus PD initiation is often delayed, if possible, for 48 to 72 hours or longer to allow for healing and lower the risk of infection and the other PD complications. Peritonitis can enhance dialysate protein loss, compromise nutrition, and permanently damage the peritoneal membrane.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Catheter malfunction – PD catheter malfunctions are common and can include failure to fill and drain completely and quickly and leakage of peritoneal fluid at the exit site.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Electrolyte abnormalities – Patients may have significant losses of sodium and other electrolytes especially in infants and children who only receive formula or breast milk feeds. In such cases, where sodium deficit is present, significant hypotension may result. PD is also associated with hyperglycemia and an increase incidence of hypokalemia and hypophosphatemia if these are not added to the dialysate [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Protein loss – Patients on PD also require increased protein intake due to amino acid losses with PD, and they also lose immunoglobulins in the dialysate, making them more susceptible to infection.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hydrothorax due to dialysate leakage into the pleural space.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hernia due to fluid in the peritoneal space and increased abdominal pressures.</p><p></p><p class="headingAnchor" id="H4746469"><span class="h3">Intermittent hemodialysis</span><span class="headingEndMark"> — </span>Intermittent HD provides the most efficient solute clearance and ultrafiltration compared with other KRT modalities. However, for children, especially critically ill patients and small children, management should be undertaken by a team (nephrologist and dialysis nurses) with expertise in administrating HD to children because of specific pediatric issues regarding obtaining vascular access, catheter selection and placement, and dialysis prescription. For small children, centers should have policies for utilizing hemodialysis equipment as the majority of the hemodialysis machines available on the market are only approved for patients greater than 15 or 20 kg.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Advantages</strong> – In the hemodynamically stable patient, no other modality is better suited for rapid and accurate small solute reduction with or without ultrafiltration. Thus, this therapy is particularly important in the pediatric population for the treatment of acute and life-threatening electrolyte abnormalities (eg, hyperkalemia), ingestions (eg, <a class="drug drug_pediatric" data-topicid="12559" href="/d/drug information/12559.html" rel="external">lithium</a>, <a class="drug drug_pediatric" data-topicid="12829" href="/d/drug information/12829.html" rel="external">aspirin</a>), drug toxicity (eg, <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a>), tumor lysis syndrome, and hyperammonemia [<a href="#rid38">38,59,60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HD access and location</strong> – Access is one of the most important components leading to the satisfactory provision of HD. The placement of acute catheters can be performed in most children at the bedside by pediatric nephrologists or intensivists. Placement of semipermanent tunneled catheters and acute catheters in very small infants is usually done in the operating room by surgeons or interventional radiologists.</p><p></p><p class="bulletIndent1">Access site is typically preferred in the right internal jugular vein due to lower risk for complication compared with other insertion sites, which include lower venous return pressures and positionality of groin lines. Subclavian veins should be avoided in order to preserve these vessels for future use as arteriovenous fistulas in patients who may progress to end-stage kidney disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Catheter selection and line placement</strong> – A wide variety of temporary vascular catheters are available for the pediatric population with different sizes (gauge) and lengths  (<a class="graphic graphic_table graphicRef57580" href="/d/graphic/57580.html" rel="external">table 4</a>) [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gauge – Catheter sizes range from 6.5 to 14 Fr and are chosen according to the vessel size based on the weight of the child  (<a class="graphic graphic_table graphicRef57580" href="/d/graphic/57580.html" rel="external">table 4</a>). Increasing the gauge of the vascular access will allow for higher blood flow rates. However, too large a catheter can lead to obstruction of vessels, resulting in reduced venous return and therefore poor flow through the dialysis circuit. Pediatric catheters are available in different lengths based on the gauge. In the United States, the smallest currently available is a 7 Fr double lumen non-tunneled catheter  (<a class="graphic graphic_table graphicRef134138" href="/d/graphic/134138.html" rel="external">table 5</a>). However, in preterm infants, even the 7 Fr catheter may be too large, and two smaller single lumen catheters placed at different access sites, including umbilical veins, may be the only option for HD.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Length – Pediatric catheters are available in different lengths based on the gauge. The selected length is based on optimal line placement of the catheter tip at the junction of the superior vena cava and the right atrium to optimize flows and limit recirculation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Components of the HD prescription</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Blood flow rate – Blood flow rate is a significant factor in determining solute clearance in patients as higher flow rates increase diffusive clearance. However, in acutely ill patients with AKI, the risks of higher blood flow and increased clearance must be weighed against instability of the patient's hemodynamic status and their ability to tolerate a higher blood flow rate. The blood flow rate is also dependent on the size and quality of the dialysis access as larger bore catheters will allow a higher blood flow rate without collapsing or causing high negative arterial pressures on the dialysis machine. Typical blood flow rates range from 3 to 10 mL/kg/minute.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dialysate flow rate – The rate of dialysate flow also determines clearance in HD but to a lesser extent than the blood flow rate. The dialysate flow rate should be set at a rate of at least 1.5 to 2 times the blood flow rate to maximize bidirectional flow between the blood and dialysate [<a href="#rid62">62</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dialysate composition – Dialysate composition is modified based on patient needs mainly to adjust for sodium, potassium, calcium, and bicarbonate levels.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dialyzer and tubing size – The small solute clearance characteristics of the dialyzer are determined by the surface area of this dialyzer. Typically, a dialyzer is prescribed with a surface area similar to the patient’s body surface area  (<a class="graphic graphic_table graphicRef134140" href="/d/graphic/134140.html" rel="external">table 6</a>).</p><p></p><p class="bulletIndent2">The extracorporeal circuit is composed of the arterial (inflow) and venous (outflow) lines (tubing) and the dialyzer. The volume of this circuit is restricted by the upper safe limit for extracorporeal blood volume that is dependent on the total blood volume of the patient. A child can tolerate up to a maximum of 10 percent of his or her total blood volume in the extracorporeal circuit, and a safe volume of the circuit is targeted at 8 percent of total blood volume of the child. For small children and infants, extracorporeal volume often exceeds 10 percent of the blood volume of the child and donor red blood cells are used to prime the extracorporeal circuit to prevent hemodynamic instability. Commercially available tubing that varies in volume should be matched to the size of the patient  (<a class="graphic graphic_table graphicRef77610" href="/d/graphic/77610.html" rel="external">table 7</a>). For neonates, tubing volume can be as low as 29 mL.</p><p></p><p class="bulletIndent2">A dialysis machine developed for infants weighing between 0.8 and 8 kg, which uses a single-lumen catheter and does not require blood priming, is being evaluated for efficacy and safety [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ultrafiltration (fluid removal) – The volume of fluid removal during a short three- to four-hour dialysis run is often very limited, especially if the patient is not hemodynamically stable or small in size.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Length of dialysis treatment – The duration of a dialysis treatment is e determined on the clearance and/or fluid removal goals.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Anticoagulation – <a class="drug drug_pediatric" data-topicid="13349" href="/d/drug information/13349.html" rel="external">Unfractionated heparin</a> is the standard anticoagulation method used for intermittent hemodialysis therapy to prevent loss of the dialysis circuit or complications with the hemodialysis catheter. A typical dose of unfractionated heparin is a bolus of 10 to 30 units/kg followed by a continuous infusion at a rate of 10 to 30 units/kg/hour. During short hemodialysis treatments, treatments can be successful with no anticoagulation or with the administration of frequent <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> flushes into the circuit.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Line placement complications – During placement of vascular catheters, complications may include blood vessel sclerosis or thrombosis, air emboli, or hemorrhage.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infection – As with all central lines, hemodialysis catheters are a potential source of infection introduction.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypotension – Rapid fluid removal may lead to episodes of hypotension.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Neurologic complications (ie, dialysis disequilibrium syndrome) – A range of neurologic manifestations including headache, nausea, blurred vision, restlessness, mental status changes, and/or seizures due to cerebral edema is associated with the initiation of HD (referred to as dialysis disequilibrium syndrome) (see  <a class="medical medical_review" href="/d/html/1851.html" rel="external">"Dialysis disequilibrium syndrome"</a>) [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potential contraindications</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hemodynamic instability may make PD or CKRT better KRT options than HD. Low blood pressure (hypotension) in the critically ill patient will limit the capacity for ultrafiltration and ultimately the ability to provide adequate treatment with HD.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Large fluid volume requirements – In critically ill patients who are anuric or oliguric and require large fluid volumes for nutrition and/or medications, it may be challenging to adequately remove fluid over the short treatment typically used with HD. As a result, PD or CKRT may be better options for those patients as they allow greater fluid removal that is continuous and gradual than HD.</p><p></p><p class="headingAnchor" id="H4746485"><span class="h3">Continuous kidney replacement therapy</span><span class="headingEndMark"> — </span>CKRT, if available, is the preferred primary modality for KRT in the critically ill, hemodynamically unstable pediatric patient [<a href="#rid20">20</a>]. CKRT includes dialysis and/or filtration treatments that operate in a continuous mode typically performed in the pediatric intensive care unit setting.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Modalities</strong> –The following modalities of CKRT are used in children.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Continuous venovenous hemodialysis (CVVHD) – Predominantly diffusion based solute clearance</p><p class="bulletIndent2"><span class="glyph">•</span>Continuous venovenous hemofiltration (CVVH) – Predominantly convection based solute clearance</p><p class="bulletIndent2"><span class="glyph">•</span>Continuous venovenous hemodiafiltration (CVVHDF) – Provides diffusion and convection based solute clearance</p><p></p><p class="bulletIndent1">Ongoing research is trying to determine which modality is better suited for specific patient conditions. Convective therapies (CVVH and CVVHDF) provide superior middle molecule clearance compared with diffusive therapy (CVVHD) [<a href="#rid65">65</a>]. These convective modalities are thought to be superior in clearing proinflammatory cytokines and may be beneficial in the treatment of patients with sepsis-related AKI. As an example, the Selective Cytopheretic Device has been shown to deactivate leukocytes within a low ionized calcium environment as with <a class="drug drug_general" data-topicid="115978" href="/d/drug information/115978.html" rel="external">regional citrate anticoagulation</a> when used in tandem with a hemodialyzer in CKRT circuits in adults [<a href="#rid66">66,67</a>]. In a small clinical trial, this device was shown it can be used safely in children with AKI and multiorgan dysfunction. Further investigation is needed to demonstrate that its use would be beneficial for treating pediatric patients with systemic inflammatory response syndrome with AKI.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Advantages</strong> – CKRT mimics native kidney function with its continual ultrafiltration and solute clearance [<a href="#rid68">68,69</a>] and has several advantages over HD and PD in the management of patients with AKI.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>CKRT is more precise in delivering the goals of solute clearance and ultrafiltration than PD. Although PD provides continuous solute clearance and ultrafiltration, the rates of clearance are variable and dependent on the patient's clinical status. CKRT can control ultrafiltration separately from solute removal, which PD cannot, allowing for greater flexibility within the prescription.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Because ultrafiltration is continuous and can be adjusted to meet the patient's needs with CKRT, there is usually no need for fluid restriction unlike that required in patients managed by HD. CKRT allows for administration of all necessary blood products, large volumes of medications, and adequate nutrition without compromising the volume status of the patient.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>CKRT provides superior uremia control compared with PD [<a href="#rid70">70,71</a>] or HD [<a href="#rid72">72,73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Components of the CKRT prescription</strong> – Prescription components are similar to those used for intermittent HD and many of the same issues apply to both modalities:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Blood flow rate – Similar to HD, blood flow rate determines solute clearance with higher flow rates increasing diffusive clearance. Blood flow is dependent on the size and quality of the dialysis access and catheter. As noted above, the balance of higher blood flow and increased clearance must be weighed against the patient's hemodynamics and their ability to tolerate a higher blood flow rate. Typical blood flow rates also range from 3 to 10 mL/kg/minute.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dialysate/replacement flow rate – The dialysate flow rate does determine clearance provided by CVVHD and CVVH, but the replacement solution plays a larger role in determining convective clearance in CVVH and CVVHDF. The standard dose for combined dialysate and replacement rate is 2000 mL/1.73m<sup>2</sup>/hour or 30 to 50 mL/kg/hour though in some cases (eg, hyperammonemia and severe tumor lysis) higher rates of 4000 to 8000 mL/1.73m<sup>2</sup>/hour may be needed [<a href="#rid74">74,75</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dialysate composition – Dialysate or replacement fluids come in a variety of commercially available formulations, but modification based on patient needs is possible [<a href="#rid76">76</a>]. However, because of potential pharmacy compounding errors when manually preparing custom solutions, caution needs to be exercised when performing these alterations [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Size of the dialyzer – Most CKRT machines have an adult and pediatric set for CKRT with limited options for dialyzer size and extracorporeal blood volume. The volume of these circuits is often &gt;10 percent of the blood volume for children who weigh less than 10 kg. Newer devices are available specifically designed for infants and neonates with smaller dialyzer surface area and blood volume  (<a class="graphic graphic_table graphicRef134141" href="/d/graphic/134141.html" rel="external">table 8</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ultrafiltration – CKRT allows for slow, continuous fluid removal which is often better tolerated in the hemodynamically unstable patients and can be adjusted on an ongoing basis depending on the fluid intake needed for medication and nutrition to attain a daily fluid balance goal.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Anticoagulation – Anticoagulation is typically required with pediatric CKRT due to the higher risk of clotting due to low blood flow rates through the small caliber catheters and tubing. In rare cases, anticoagulation may not be required in larger patients with high blood flow rates or in patients with coagulopathies (ie, liver failure patients).</p><p></p><p class="bulletIndent2">Anticoagulation therapy can be provided regionally or systematically. Regional anticoagulation is typically the preferred method of anticoagulation at most pediatric centers, but this choice is highly dependent on patient characteristics and the experience of the center and its staff. (See  <a class="medical medical_review" href="/d/html/16855.html" rel="external">"Anticoagulation for continuous kidney replacement therapy"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Regional anticoagulation – Citrate is the preferred method of regional anticoagulation in pediatric patients. Regional anticoagulation should be considered in pediatric patients with significant bleeding risk, especially central nervous system hemorrhage risk (see  <a class="medical medical_review" href="/d/html/16855.html" rel="external">"Anticoagulation for continuous kidney replacement therapy"</a>). There are commercial preparations of sodium citrate or anticoagulant citrate dextrose solution designed for CKRT use. However, citrate anticoagulation has several key requirements which must be considered including separate central access for calcium infusion, arterial line for accurate lab draws, dialysate with no calcium and the need to measure ionized calcium levels frequently. Relative contraindications for citrate anticoagulation include liver failure, mitochondrial disorders, and infants as they are at risk of citrate accumulation. Complications with citrate anticoagulation include hypo- or hypercalcemia, hypernatremia, hyperglycemia, and metabolic alkalosis. <a class="drug drug_general" data-topicid="115978" href="/d/drug information/115978.html" rel="external">Regional citrate anticoagulation</a> has shown longer circuit life than heparin in several pediatric studies [<a href="#rid77">77,78</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Systemic anticoagulation – <a class="drug drug_pediatric" data-topicid="13349" href="/d/drug information/13349.html" rel="external">Unfractionated heparin</a> is the most common form of systemic anticoagulation for CKRT in pediatric patients. (See  <a class="medical medical_review" href="/d/html/16855.html" rel="external">"Anticoagulation for continuous kidney replacement therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Challenges</strong> – The main disadvantages of CKRT are its complexity and expense, which limit its general availability. While it is an established therapy at many tertiary care hospitals in resource-abundant settings, CKRT requires significant technological expertise and resource allocation, including trained intensive care unit nurses to monitor and adjust CKRT, and pediatric pharmacy support for modification of dialysate composition [<a href="#rid39">39,79</a>].</p><p></p><p class="bulletIndent1">Other challenges include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Central line access – Like HD, adequate vascular access is essential. An additional central line may also be required for the administration of <a class="drug drug_pediatric" data-topicid="12651" href="/d/drug information/12651.html" rel="external">calcium chloride</a> as part of <a class="drug drug_general" data-topicid="115978" href="/d/drug information/115978.html" rel="external">regional citrate anticoagulation</a> protocols.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Limitations for small infants and neonates – For small infants and neonates, limitations are based on dialyzer and tubing size. In many cases, similar to intermittent HD, donor blood is needed to prime the extracorporeal circuit, which may expose these infants to transfusion risks and hypotension [<a href="#rid80">80,81</a>].</p><p></p><p class="bulletIndent2">The development of dialyzers specifically designed for neonates and small infants that require lower priming volumes of blood and are able to run accurately at low blood flows between 5 and 50 mL/min via smaller-sized dialysis catheters have increased the feasibility of providing CKRT to critically ill infants  (<a class="graphic graphic_table graphicRef134141" href="/d/graphic/134141.html" rel="external">table 8</a>) [<a href="#rid82">82,83</a>]. The CARPEDIEM machine is now approved in several countries, including the United States, for CKRT in patients weighing between 2 to 10 kg [<a href="#rid82">82,84</a>]. This system has two dialyzer cartridges which have priming volumes of 32 and 41 mL. They have successfully utilized small-bore dialysis catheters (4 to 7 Fr) with blood flow rates as low as 5 mL/min. However, the experience using this system in critically ill patients has been limited to a few tertiary centers.</p><p></p><p class="bulletIndent2">A multicenter study reported the successful use of an ultrafiltration device (Aquadex FlexFlow System) in critically ill infants and children, including neonates, which had been initially designed for adult-sized patients [<a href="#rid81">81</a>]. Although this device has a small extracorporeal volume of 33 mL, a blood prime was still needed for patients weighing &lt;4 kg.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Effect on medications – Careful attention must be paid to medications that a patient is receiving because CKRT may alter the clearance of these drugs, especially those that are of lower molecular weight, water soluble, and not highly protein bound. Close collaboration with a pharmacist knowledgeable about drug dosing is a key component for the care of children receiving CKRT.</p><p></p><p class="headingAnchor" id="H558284398"><span class="h3">Prolonged intermittent kidney replacement therapy</span><span class="headingEndMark"> — </span>PIKRT is defined as intermittent KRT performed over a prolonged time period (6 to 12 hours) using conventional HD machines. Adult trials have shown PIKRT to be more cost effective and have similar efficacy as CKRT. Pediatric studies are limited to one small case series of four patients that reported the use of lower ultrafiltration and blood flow rates with excellent survival [<a href="#rid85">85</a>]. (See  <a class="medical medical_review" href="/d/html/1927.html" rel="external">"Kidney replacement therapy (dialysis) in acute kidney injury in adults: Indications, timing, and dialysis dose", section on 'Prolonged intermittent kidney replacement therapy'</a>.)</p><p class="headingAnchor" id="H4746501"><span class="h2">Comparisons of modalities</span><span class="headingEndMark"> — </span>There have been no prospective clinical trials comparing the three modalities (PD, HD, and CKRT) for treatment of children with AKI. Several trials in adults have demonstrated no difference in survival between CKRT and HD. (See  <a class="medical medical_review" href="/d/html/1927.html" rel="external">"Kidney replacement therapy (dialysis) in acute kidney injury in adults: Indications, timing, and dialysis dose"</a>.)</p><p>Observational data in children with AKI include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective population-based study from the United Kingdom of children who received KRT from 2005 to 2012 reported improved survival with PD compared with CKRT [<a href="#rid86">86</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a multicenter retrospective study of 226 children who received KRT from 1992 to 1998, survival rates were 40, 49, and 81 percent for hemofiltration (HF), PD, and HD, respectively [<a href="#rid87">87</a>]. However, in this cohort, the use of inotropic pressors was the most important factor for survival, and its use was greatest in children on HF and larger patients were selected for HD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of 42 children following congenital heart disease repair, there was no difference in mortality between patients who were treated with PD and CKRT [<a href="#rid71">71</a>]. However, CKRT was superior to PD in terms of fluid balance, solute clearance, and ability to provide adequate nutrition.</p><p></p><p>However, available evidence for the optimal treatment is limited by the lack of control for confounding factors, such as severity of illness and underlying etiology of AKI. This lack of data has left unresolved the persistent debate on whether initiation of CKRT contributes to kidney injury by reducing renal blood flow.</p><p>Although an alternate medical approach to treat pediatric AKI has been proposed, which uses a regimen of high-dose diuretics and/or medications to augment renal blood flow (eg, <a class="drug drug_pediatric" data-topicid="13248" href="/d/drug information/13248.html" rel="external">dopamine</a>) [<a href="#rid88">88</a>], this approach increases the metabolic demand of the kidneys, which has the potential to be more harmful than CKRT. This approach would also seem to require an already damaged organ to work even harder in a critical environment. As a result, further research is needed to determine the best approach to treat pediatric AKI. In particular, randomized trials that compare regimens of early initiation of CKRT, AKI medical management (eg, diuretics), and current standard care would be useful in guiding clinical decision making in children with AKI.</p><p class="headingAnchor" id="H4746509"><span class="h1">DISCONTINUATION</span><span class="headingEndMark"> — </span>The factors determining when or how KRT should be discontinued (or transitioned to another modality) are even less well described than the factors determining initiation. No clear approach for dialysis step down or discontinuation has been defined for patients with AKI. Just as with initiation, KRT cessation or modality change is influenced by multiple factors such as urine output (including response to diuretic therapy), hemodynamic stability, respiratory, nutritional and volume status, and changes in underlying disease and overall prognosis. Other considerations may include ongoing resource use, staff availability, family/caregiver wishes, and long-term patient needs. For example, if a patient with multiorgan failure has improved and is at the point of extubation, it may be reasonable to change the patient from a continuous therapy to intermittent HD to facilitate patient rehabilitation and transfer from the pediatric intensive care unit to the ward.</p><p>Guidelines or strategies have not been published regarding transitioning patients off of KRT. Unlike mechanical ventilation weaning, which has been studied extensively, the approach to tapering and discontinuation of KRT is an area ripe for investigation.</p><p class="headingAnchor" id="H4746516"><span class="h1">OUTCOMES</span><span class="headingEndMark"> — </span>Retrospective data demonstrate that the overall survival rates range between 50 and 75 percent in children with AKI who received KRT [<a href="#rid9">9,86,87,89-91</a>]. Factors that increase mortality include:</p><p class="bulletIndent1"><span class="glyph">●</span>Underlying diseases that cause secondary kidney failure, including bone marrow failure, hepatic failure, oncohematologic and severe pulmonary disease. In addition, stem cell and solid organ transplantation (eg, lung and liver) are associated with poorer survival [<a href="#rid9">9,86,89,92</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypotension at the onset of KRT [<a href="#rid87">87</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of inotropic agents anytime during the course of KRT [<a href="#rid87">87,91</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Degree of fluid overload present on initiation of KRT [<a href="#rid9">9,21,91</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients under one year of age [<a href="#rid86">86</a>].</p><p></p><p>Additional studies are needed to determine whether other measures including chronic kidney disease, hypertension, and proteinuria during and after KRT are predictive for long-term outcome.</p><p class="headingAnchor" id="H3513474693"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110753.html" rel="external">"Society guideline links: Acute kidney injury in children"</a>.)</p><p class="headingAnchor" id="H4746523"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute kidney injury (AKI) and role of kidney replacement therapy (KRT)</strong> – For infants and children, AKI is an independent predictor of morbidity and mortality, especially in critically ill patients. KRT may prevent and correct the adverse and potentially life-threatening complications and improve survival. (See <a class="local">'Acute kidney injury and mortality: Potential role of kidney replacement therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Urgent indications for KRT include (see <a class="local">'Urgent indications'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Children with clinically significant fluid overload with evidence of escalating ventilatory requirements (typically seen in patients with &gt;15 percent fluid overload). (See <a class="local">'Fluid overload'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Critically ill children with persistent hyperkalemia (eg, potassium level &gt;6.5 mEq/L) that is refractory to medical management as they are at risk for life-threatening cardiac conductin abnormalities due to hypokalemia. (See  <a class="medical medical_review" href="/d/html/14274.html" rel="external">"Causes, clinical manifestations, diagnosis, and evaluation of hyperkalemia in children", section on 'Cardiac conduction abnormalities'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Critically ill children with persistent metabolic acidosis that is refractory to medical management.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Children with complications due to uremia, including pericarditis, encephalopathy, or unexplained change in mental status and bleeding.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Children with exposure to either endogenous or exogenous toxins, which are dialyzable, that are inadequately excreted by the kidney.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nonurgent indications include (see <a class="local">'Nonurgent indications'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Although there are insufficient data to support evidence-based guidelines that include quantifiable values for uremia, we suggest that KRT should be initiated early based on a serum blood urea nitrogen (BUN) level between 80 and 100 mg/dL prior to the development of significant signs and symptoms of acute kidney failure rather than delaying dialysis until the child is symptomatic (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Severe acute kidney injury'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients who remain oliguric despite diuretic therapy with high volume requirements (eg, nutrition, medications, and/or blood products) for their care.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Modalities</strong> – Several KRT modalities, including peritoneal dialysis, intermittent hemodialysis, and continuous KRT, are available to manage pediatric patients with AKI. PD is the most common modality utilized in pediatric dialysis, particularly in the smallest children. Data are insufficient to recommend one modality over another. Thus, the selection of modality of KRT is based on patient factors (size, underlying illness, ability to obtain access), local expertise and experience, and available resources. (See <a class="local">'Modality'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multidisciplinary team</strong> – Initiating KRT in a critically ill child requires collaboration among the nephrologists, intensivists, and other subspecialists caring for the child. Early discussion and planning will facilitate the process and allow for more rapid intervention, thereby improving survival outcomes. (See <a class="local">'Kidney replacement therapy modalities and clinical considerations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcome</strong> – Retrospective data demonstrate the overall survival rates range between 50 and 75 percent in children with AKI who received KRT. Risk factors for mortality include the underlying disease, hypotension, and significant fluid overload at the start of KRT; use of inotropic therapy during KRT; and age under one year. (See <a class="local">'Outcomes'</a> above.)</p><p></p><p class="headingAnchor" id="H1021667128"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Patrick D Brophy, MD (deceased), who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Liu KD, Goldstein SL, Vijayan A, et al. AKI!Now Initiative: Recommendations for Awareness, Recognition, and Management of AKI. Clin J Am Soc Nephrol 2020; 15:1838.</a></li><li><a class="nounderline abstract_t">Roy JP, Devarajan P. Acute Kidney Injury: Diagnosis and Management. Indian J Pediatr 2020; 87:600.</a></li><li><a class="nounderline abstract_t">Fragasso T, Ricci Z, Goldstein SL. Pediatric Acute Kidney Injury. Contrib Nephrol 2018; 193:113.</a></li><li><a class="nounderline abstract_t">Kaddourah A, Basu RK, Goldstein SL, et al. Oliguria and Acute Kidney Injury in Critically Ill Children: Implications for Diagnosis and Outcomes. Pediatr Crit Care Med 2019; 20:332.</a></li><li><a class="nounderline abstract_t">Sutherland SM, Byrnes JJ, Kothari M, et al. AKI in hospitalized children: comparing the pRIFLE, AKIN, and KDIGO definitions. Clin J Am Soc Nephrol 2015; 10:554.</a></li><li><a class="nounderline abstract_t">Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 2012; 120:c179.</a></li><li><a class="nounderline abstract_t">Sutherland SM, Ji J, Sheikhi FH, et al. AKI in hospitalized children: epidemiology and clinical associations in a national cohort. Clin J Am Soc Nephrol 2013; 8:1661.</a></li><li><a class="nounderline abstract_t">Diaz F, Benfield M, Brown L, Hayes L. Fluid overload and outcomes in critically ill children: A single center prospective cohort study. J Crit Care 2017; 39:209.</a></li><li><a class="nounderline abstract_t">Cortina G, McRae R, Hoq M, et al. Mortality of Critically Ill Children Requiring Continuous Renal Replacement Therapy: Effect of Fluid Overload, Underlying Disease, and Timing of Initiation. Pediatr Crit Care Med 2019; 20:314.</a></li><li><a class="nounderline abstract_t">Schneider J, Khemani R, Grushkin C, Bart R. Serum creatinine as stratified in the RIFLE score for acute kidney injury is associated with mortality and length of stay for children in the pediatric intensive care unit. Crit Care Med 2010; 38:933.</a></li><li><a class="nounderline abstract_t">Williams DM, Sreedhar SS, Mickell JJ, Chan JC. Acute kidney failure: a pediatric experience over 20 years. Arch Pediatr Adolesc Med 2002; 156:893.</a></li><li><a class="nounderline abstract_t">Chen J, Li X, Bai Z, et al. Association of Fluid Accumulation with Clinical Outcomes in Critically Ill Children with Severe Sepsis. PLoS One 2016; 11:e0160093.</a></li><li><a class="nounderline abstract_t">Li Y, Wang J, Bai Z, et al. Early fluid overload is associated with acute kidney injury and PICU mortality in critically ill children. Eur J Pediatr 2016; 175:39.</a></li><li><a class="nounderline abstract_t">Lex DJ, Tóth R, Czobor NR, et al. Fluid Overload Is Associated With Higher Mortality and Morbidity in Pediatric Patients Undergoing Cardiac Surgery. Pediatr Crit Care Med 2016; 17:307.</a></li><li><a class="nounderline abstract_t">Mah KE, Hao S, Sutherland SM, et al. Fluid overload independent of acute kidney injury predicts poor outcomes in neonates following congenital heart surgery. Pediatr Nephrol 2018; 33:511.</a></li><li><a class="nounderline abstract_t">Boyd JH, Forbes J, Nakada TA, et al. Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med 2011; 39:259.</a></li><li><a class="nounderline abstract_t">Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 2000; 356:26.</a></li><li><a class="nounderline abstract_t">Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8:R204.</a></li><li><a class="nounderline abstract_t">Devarajan P. Cellular and molecular derangements in acute tubular necrosis. Curr Opin Pediatr 2005; 17:193.</a></li><li><a class="nounderline abstract_t">Goldstein SL, Somers MJ, Baum MA, et al. Pediatric patients with multi-organ dysfunction syndrome receiving continuous renal replacement therapy. Kidney Int 2005; 67:653.</a></li><li><a class="nounderline abstract_t">Sutherland SM, Zappitelli M, Alexander SR, et al. Fluid overload and mortality in children receiving continuous renal replacement therapy: the prospective pediatric continuous renal replacement therapy registry. Am J Kidney Dis 2010; 55:316.</a></li><li><a class="nounderline abstract_t">Hassinger AB, Wald EL, Goodman DM. Early postoperative fluid overload precedes acute kidney injury and is associated with higher morbidity in pediatric cardiac surgery patients. Pediatr Crit Care Med 2014; 15:131.</a></li><li><a class="nounderline abstract_t">Lima L, Menon S, Goldstein SL, Basu RK. Timing of Fluid Overload and Association With Patient Outcome. Pediatr Crit Care Med 2021; 22:114.</a></li><li><a class="nounderline abstract_t">Davis AL, Carcillo JA, Aneja RK, et al. American College of Critical Care Medicine Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock. Crit Care Med 2017; 45:1061.</a></li><li><a class="nounderline abstract_t">Devarajan P. Emerging urinary biomarkers in the diagnosis of acute kidney injury. Expert Opin Med Diagn 2008; 2:387.</a></li><li><a class="nounderline abstract_t">Zappitelli M, Washburn KK, Arikan AA, et al. Urine neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in critically ill children: a prospective cohort study. Crit Care 2007; 11:R84.</a></li><li><a class="nounderline abstract_t">Filho LT, Grande AJ, Colonetti T, et al. Accuracy of neutrophil gelatinase-associated lipocalin for acute kidney injury diagnosis in children: systematic review and meta-analysis. Pediatr Nephrol 2017; 32:1979.</a></li><li><a class="nounderline abstract_t">Han WK, Bailly V, Abichandani R, et al. Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 2002; 62:237.</a></li><li><a class="nounderline abstract_t">Parikh CR, Mishra J, Thiessen-Philbrook H, et al. Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. Kidney Int 2006; 70:199.</a></li><li><a class="nounderline abstract_t">Penk J, Gist KM, Wald EL, et al. Furosemide response predicts acute kidney injury in children after cardiac surgery. J Thorac Cardiovasc Surg 2019; 157:2444.</a></li><li><a class="nounderline abstract_t">Goldstein SL, Chawla LS. Renal angina. Clin J Am Soc Nephrol 2010; 5:943.</a></li><li><a class="nounderline abstract_t">Basu RK, Chawla LS, Wheeler DS, Goldstein SL. Renal angina: an emerging paradigm to identify children at risk for acute kidney injury. Pediatr Nephrol 2012; 27:1067.</a></li><li><a class="nounderline abstract_t">Basu RK, Kaddourah A, Goldstein SL, AWARE Study Investigators. Assessment of a renal angina index for prediction of severe acute kidney injury in critically ill children: a multicentre, multinational, prospective observational study. Lancet Child Adolesc Health 2018; 2:112.</a></li><li><a class="nounderline abstract_t">Sethi SK, Raghunathan V, Shah S, et al. Fluid Overload and Renal Angina Index at Admission Are Associated With Worse Outcomes in Critically Ill Children. Front Pediatr 2018; 6:118.</a></li><li><a class="nounderline abstract_t">Huang L, Shi T, Quan W, et al. Assessment of early renal angina index for prediction of subsequent severe acute kidney injury during septic shock in children. BMC Nephrol 2020; 21:358.</a></li><li><a class="nounderline abstract_t">Abbasi A, Mehdipour Rabori P, Farajollahi R, et al. Discriminatory Precision of Renal Angina Index in Predicting Acute Kidney Injury in Children; a Systematic Review and Meta-Analysis. Arch Acad Emerg Med 2020; 8:e39.</a></li><li class="breakAll">Benfield MR, Bunchman TE. Management of acute renal failure. In: Pediatric Nephrology, 5th ed, Avner ED, Harmon WE, Niaudet P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. p.1253.</li><li><a class="nounderline abstract_t">Parakininkas D, Greenbaum LA. Comparison of solute clearance in three modes of continuous renal replacement therapy. Pediatr Crit Care Med 2004; 5:269.</a></li><li><a class="nounderline abstract_t">Bunchman TE, Maxvold NJ, Brophy PD. Pediatric convective hemofiltration: Normocarb replacement fluid and citrate anticoagulation. Am J Kidney Dis 2003; 42:1248.</a></li><li><a class="nounderline abstract_t">Goldstein SL. Overview of pediatric renal replacement therapy in acute renal failure. Artif Organs 2003; 27:781.</a></li><li><a class="nounderline abstract_t">Kashani K, Rosner MH, Haase M, et al. Quality Improvement Goals for Acute Kidney Injury. Clin J Am Soc Nephrol 2019; 14:941.</a></li><li><a class="nounderline abstract_t">Nkoy AB, Ndiyo YM, Matoka TT, et al. A promising pediatric peritoneal dialysis experience in a resource-limited setting with the support of saving young lives program. Perit Dial Int 2020; 40:504.</a></li><li><a class="nounderline abstract_t">McCulloch M, Luyckx VA, Cullis B, et al. Challenges of access to kidney care for children in low-resource settings. Nat Rev Nephrol 2021; 17:33.</a></li><li><a class="nounderline abstract_t">Auron A, Warady BA, Simon S, et al. Use of the multipurpose drainage catheter for the provision of acute peritoneal dialysis in infants and children. Am J Kidney Dis 2007; 49:650.</a></li><li><a class="nounderline abstract_t">Bunchman TE. Acute peritoneal dialysis access in infant renal failure. Perit Dial Int 1996; 16 Suppl 1:S509.</a></li><li><a class="nounderline abstract_t">Nash MA, Russo JC. Neonatal lactic acidosis and renal failure: the role of peritoneal dialysis. J Pediatr 1977; 91:101.</a></li><li><a class="nounderline abstract_t">Grodstein GP, Blumenkrantz MJ, Kopple JD, et al. Glucose absorption during continuous ambulatory peritoneal dialysis. Kidney Int 1981; 19:564.</a></li><li><a class="nounderline abstract_t">Barletta JF, Barletta GM, Brophy PD, et al. Medication errors and patient complications with continuous renal replacement therapy. Pediatr Nephrol 2006; 21:842.</a></li><li><a class="nounderline abstract_t">Podel J, Hodelin-Wetzel R, Saha DC, Burns G. Glucose absorption in acute peritoneal dialysis. J Ren Nutr 2000; 10:93.</a></li><li><a class="nounderline abstract_t">Reznik VM, Griswold WR, Peterson BM, et al. Peritoneal dialysis for acute renal failure in children. Pediatr Nephrol 1991; 5:715.</a></li><li><a class="nounderline abstract_t">Margetts P. Heparin and the peritoneal membrane. Perit Dial Int 2009; 29:16.</a></li><li><a class="nounderline abstract_t">Warady BA, Bakkaloglu S, Newland J, et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. Perit Dial Int 2012; 32 Suppl 2:S32.</a></li><li><a class="nounderline abstract_t">Cullis B, Abdelraheem M, Abrahams G, et al. Peritoneal dialysis for acute kidney injury. Perit Dial Int 2014; 34:494.</a></li><li><a class="nounderline abstract_t">Flynn JT, Kershaw DB, Smoyer WE, et al. Peritoneal dialysis for management of pediatric acute renal failure. Perit Dial Int 2001; 21:390.</a></li><li><a class="nounderline abstract_t">Phadke KD, Dinakar C. The challenges of treating children with renal failure in a developing country. Perit Dial Int 2001; 21 Suppl 3:S326.</a></li><li><a class="nounderline abstract_t">Flynn JT. Choice of dialysis modality for management of pediatric acute renal failure. Pediatr Nephrol 2002; 17:61.</a></li><li><a class="nounderline abstract_t">Bouty A, Faure A, Shaw L, et al. Is peritoneal dialysis feasible after laparotomy in children? A case-control series to compare outcomes. J Pediatr Urol 2017; 13:612.e1.</a></li><li><a class="nounderline abstract_t">Kim JE, Park SJ, Oh JY, et al. Noninfectious Complications of Peritoneal Dialysis in Korean Children: A 26-Year Single-Center Study. Yonsei Med J 2015; 56:1359.</a></li><li><a class="nounderline abstract_t">McBryde KD, Kershaw DB, Bunchman TE, et al. Renal replacement therapy in the treatment of confirmed or suspected inborn errors of metabolism. J Pediatr 2006; 148:770.</a></li><li><a class="nounderline abstract_t">Brophy PD, Flynn JT, Kershaw DB, et al. Pediatric overdose: effective treatment with high-efficiency hemodialysis (abstract). J Am Soc Neprhol 1999; 10:137A.</a></li><li><a class="nounderline abstract_t">Bunchman TE, Gardner JJ, Kershaw DB, Maxvoid JN. Vascular access for hemodialysis or CVVH(D) in infants and children. Dial Transplant 1994; 23:314.</a></li><li><a class="nounderline abstract_t">Müller D, Goldstein SL. Hemodialysis in children with end-stage renal disease. Nat Rev Nephrol 2011; 7:650.</a></li><li><a class="nounderline abstract_t">Coulthard MG, Crosier J, Griffiths C, et al. Haemodialysing babies weighing &lt;8 kg with the Newcastle infant dialysis and ultrafiltration system (Nidus): comparison with peritoneal and conventional haemodialysis. Pediatr Nephrol 2014; 29:1873.</a></li><li><a class="nounderline abstract_t">Arieff AI. Dialysis disequilibrium syndrome: current concepts on pathogenesis and prevention. Kidney Int 1994; 45:629.</a></li><li><a class="nounderline abstract_t">Troyanov S, Cardinal J, Geadah D, et al. Solute clearances during continuous venovenous haemofiltration at various ultrafiltration flow rates using Multiflow-100 and HF1000 filters. Nephrol Dial Transplant 2003; 18:961.</a></li><li><a class="nounderline abstract_t">Tumlin JA, Galphin CM, Tolwani AJ, et al. A Multi-Center, Randomized, Controlled, Pivotal Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device in Patients with Acute Kidney Injury. PLoS One 2015; 10:e0132482.</a></li><li><a class="nounderline abstract_t">Tumlin JA, Chawla L, Tolwani AJ, et al. The effect of the selective cytopheretic device on acute kidney injury outcomes in the intensive care unit: a multicenter pilot study. Semin Dial 2013; 26:616.</a></li><li><a class="nounderline abstract_t">Bunchman TE, Donckerwolcke RA. Continuous arterial-venous diahemofiltration and continuous veno-venous diahemofiltration in infants and children. Pediatr Nephrol 1994; 8:96.</a></li><li><a class="nounderline abstract_t">Forni LG, Hilton PJ. Continuous hemofiltration in the treatment of acute renal failure. N Engl J Med 1997; 336:1303.</a></li><li class="breakAll">Bandeira MF, Gam A, Zagury A, et al. Renal Replacement Therapy (RRT) in Acute Renal Failure (ARF) in Critically Ill Children Under 10 kg. Poster/Abstract Annual Dialysis Conference Tampa, FL, 2005.</li><li><a class="nounderline abstract_t">Fleming F, Bohn D, Edwards H, et al. Renal replacement therapy after repair of congenital heart disease in children. A comparison of hemofiltration and peritoneal dialysis. J Thorac Cardiovasc Surg 1995; 109:322.</a></li><li><a class="nounderline abstract_t">Clark WR, Mueller BA, Alaka KJ, Macias WL. A comparison of metabolic control by continuous and intermittent therapies in acute renal failure. J Am Soc Nephrol 1994; 4:1413.</a></li><li><a class="nounderline abstract_t">Swartz RD, Bustami RT, Daley JM, et al. Estimating the impact of renal replacement therapy choice on outcome in severe acute renal failure. Clin Nephrol 2005; 63:335.</a></li><li><a class="nounderline abstract_t">Spinale JM, Laskin BL, Sondheimer N, et al. High-dose continuous renal replacement therapy for neonatal hyperammonemia. Pediatr Nephrol 2013; 28:983.</a></li><li><a class="nounderline abstract_t">Hanudel M, Avasare S, Tsai E, et al. A biphasic dialytic strategy for the treatment of neonatal hyperammonemia. Pediatr Nephrol 2014; 29:315.</a></li><li><a class="nounderline abstract_t">McBryde KD, Bunchman TE, Kudelka TL, et al. Hyperosmolar solutions in continuous renal replacement therapy for hyperosmolar acute renal failure: a preliminary report. Pediatr Crit Care Med 2005; 6:220.</a></li><li><a class="nounderline abstract_t">Rico MP, Fernández Sarmiento J, Rojas Velasquez AM, et al. Regional citrate anticoagulation for continuous renal replacement therapy in children. Pediatr Nephrol 2017; 32:703.</a></li><li><a class="nounderline abstract_t">Zaoral T, Hladík M, Zapletalová J, et al. Circuit Lifetime With Citrate Versus Heparin in Pediatric Continuous Venovenous Hemodialysis. Pediatr Crit Care Med 2016; 17:e399.</a></li><li><a class="nounderline abstract_t">Brophy PD, Somers MJ, Baum MA, et al. Multi-centre evaluation of anticoagulation in patients receiving continuous renal replacement therapy (CRRT). Nephrol Dial Transplant 2005; 20:1416.</a></li><li><a class="nounderline abstract_t">Askenazi DJ, Goldstein SL, Koralkar R, et al. Continuous renal replacement therapy for children ≤10 kg: a report from the prospective pediatric continuous renal replacement therapy registry. J Pediatr 2013; 162:587.</a></li><li><a class="nounderline abstract_t">Menon S, Broderick J, Munshi R, et al. Kidney Support in Children using an Ultrafiltration Device: A Multicenter, Retrospective Study. Clin J Am Soc Nephrol 2019; 14:1432.</a></li><li><a class="nounderline abstract_t">Ronco C, Garzotto F, Brendolan A, et al. Continuous renal replacement therapy in neonates and small infants: development and first-in-human use of a miniaturised machine (CARPEDIEM). Lancet 2014; 383:1807.</a></li><li><a class="nounderline abstract_t">Garzotto F, Vidal E, Ricci Z, et al. Continuous kidney replacement therapy in critically ill neonates and infants: a retrospective analysis of clinical results with a dedicated device. Pediatr Nephrol 2020; 35:1699.</a></li><li><a class="nounderline abstract_t">Lorenzin A, Garzotto F, Alghisi A, et al. CVVHD treatment with CARPEDIEM: small solute clearance at different blood and dialysate flows with three different surface area filter configurations. Pediatr Nephrol 2016; 31:1659.</a></li><li><a class="nounderline abstract_t">Ali US, Arya MK. Efficacy and safety of prolonged daily hemodialysis in critically ill children weighing less than 10 kg. Hemodial Int 2020; 24:108.</a></li><li><a class="nounderline abstract_t">Westrope CA, Fleming S, Kapetanstrataki M, et al. Renal Replacement Therapy in the Critically Ill Child. Pediatr Crit Care Med 2018; 19:210.</a></li><li><a class="nounderline abstract_t">Bunchman TE, McBryde KD, Mottes TE, et al. Pediatric acute renal failure: outcome by modality and disease. Pediatr Nephrol 2001; 16:1067.</a></li><li><a class="nounderline abstract_t">Chawla LS, Kellum JA, Ronco C. Permissive hypofiltration. Crit Care 2012; 16:317.</a></li><li><a class="nounderline abstract_t">Symons JM, Chua AN, Somers MJ, et al. Demographic characteristics of pediatric continuous renal replacement therapy: a report of the prospective pediatric continuous renal replacement therapy registry. Clin J Am Soc Nephrol 2007; 2:732.</a></li><li><a class="nounderline abstract_t">Hui-Stickle S, Brewer ED, Goldstein SL. Pediatric ARF epidemiology at a tertiary care center from 1999 to 2001. Am J Kidney Dis 2005; 45:96.</a></li><li><a class="nounderline abstract_t">Choi SJ, Ha EJ, Jhang WK, Park SJ. Factors Associated With Mortality in Continuous Renal Replacement Therapy for Pediatric Patients With Acute Kidney Injury. Pediatr Crit Care Med 2017; 18:e56.</a></li><li><a class="nounderline abstract_t">Flores FX, Brophy PD, Symons JM, et al. Continuous renal replacement therapy (CRRT) after stem cell transplantation. A report from the prospective pediatric CRRT Registry Group. Pediatr Nephrol 2008; 23:625.</a></li></ol></div><div id="topicVersionRevision">Topic 15895 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32317329" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : AKI!Now Initiative: Recommendations for Awareness, Recognition, and Management of AKI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31713215" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Acute Kidney Injury: Diagnosis and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29393128" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pediatric Acute Kidney Injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30676490" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Oliguria and Acute Kidney Injury in Critically Ill Children: Implications for Diagnosis and Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25649155" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : AKI in hospitalized children: comparing the pRIFLE, AKIN, and KDIGO definitions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22890468" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : KDIGO clinical practice guidelines for acute kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23833312" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : AKI in hospitalized children: epidemiology and clinical associations in a national cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28254390" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Fluid overload and outcomes in critically ill children: A single center prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30431556" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Mortality of Critically Ill Children Requiring Continuous Renal Replacement Therapy: Effect of Fluid Overload, Underlying Disease, and Timing of Initiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20124891" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Serum creatinine as stratified in the RIFLE score for acute kidney injury is associated with mortality and length of stay for children in the pediatric intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12197796" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Acute kidney failure: a pediatric experience over 20 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467522" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Association of Fluid Accumulation with Clinical Outcomes in Critically Ill Children with Severe Sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26206387" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Early fluid overload is associated with acute kidney injury and PICU mortality in critically ill children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26914622" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Fluid Overload Is Associated With Higher Mortality and Morbidity in Pediatric Patients Undergoing Cardiac Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29128923" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Fluid overload independent of acute kidney injury predicts poor outcomes in neonates following congenital heart surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20975548" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10892761" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15312219" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15800411" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Cellular and molecular derangements in acute tubular necrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15673313" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pediatric patients with multi-organ dysfunction syndrome receiving continuous renal replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20042260" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Fluid overload and mortality in children receiving continuous renal replacement therapy: the prospective pediatric continuous renal replacement therapy registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24366508" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Early postoperative fluid overload precedes acute kidney injury and is associated with higher morbidity in pediatric cardiac surgery patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32947381" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Timing of Fluid Overload and Association With Patient Outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28509730" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : American College of Critical Care Medicine Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19079800" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Emerging urinary biomarkers in the diagnosis of acute kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17678545" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Urine neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in critically ill children: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28616656" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Accuracy of neutrophil gelatinase-associated lipocalin for acute kidney injury diagnosis in children: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12081583" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16710348" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30745052" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Furosemide response predicts acute kidney injury in children after cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20299370" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Renal angina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22012033" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Renal angina: an emerging paradigm to identify children at risk for acute kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30035208" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Assessment of a renal angina index for prediction of severe acute kidney injury in critically ill children: a multicentre, multinational, prospective observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29765932" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Fluid Overload and Renal Angina Index at Admission Are Associated With Worse Outcomes in Critically Ill Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32854655" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Assessment of early renal angina index for prediction of subsequent severe acute kidney injury during septic shock in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32259128" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Discriminatory Precision of Renal Angina Index in Predicting Acute Kidney Injury in Children; a Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32259128" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Discriminatory Precision of Renal Angina Index in Predicting Acute Kidney Injury in Children; a Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15115566" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Comparison of solute clearance in three modes of continuous renal replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14655197" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pediatric convective hemofiltration: Normocarb replacement fluid and citrate anticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12940899" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Overview of pediatric renal replacement therapy in acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31101671" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Quality Improvement Goals for Acute Kidney Injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32063192" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A promising pediatric peritoneal dialysis experience in a resource-limited setting with the support of saving young lives program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33005036" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Challenges of access to kidney care for children in low-resource settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17472847" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Use of the multipurpose drainage catheter for the provision of acute peritoneal dialysis in infants and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8728258" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Acute peritoneal dialysis access in infant renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/874645" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Neonatal lactic acidosis and renal failure: the role of peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7241890" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Glucose absorption during continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16622714" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Medication errors and patient complications with continuous renal replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10757822" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Glucose absorption in acute peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1768584" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Peritoneal dialysis for acute renal failure in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19164247" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Heparin and the peritoneal membrane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22851742" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25074995" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Peritoneal dialysis for acute kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11587403" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Peritoneal dialysis for management of pediatric acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11887846" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The challenges of treating children with renal failure in a developing country.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11793137" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Choice of dialysis modality for management of pediatric acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28571995" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Is peritoneal dialysis feasible after laparotomy in children? A case-control series to compare outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26256980" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Noninfectious Complications of Peritoneal Dialysis in Korean Children: A 26-Year Single-Center Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16769384" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Renal replacement therapy in the treatment of confirmed or suspected inborn errors of metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Pediatric overdose: effective treatment with high-efficiency hemodialysis (abstract)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Vascular access for hemodialysis or CVVH(D) in infants and children</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21894181" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Hemodialysis in children with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25125229" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Haemodialysing babies weighing&lt;8 kg with the Newcastle infant dialysis and ultrafiltration system (Nidus): comparison with peritoneal and conventional haemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8196263" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Dialysis disequilibrium syndrome: current concepts on pathogenesis and prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12686672" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Solute clearances during continuous venovenous haemofiltration at various ultrafiltration flow rates using Multiflow-100 and HF1000 filters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26244978" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : A Multi-Center, Randomized, Controlled, Pivotal Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device in Patients with Acute Kidney Injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23106607" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The effect of the selective cytopheretic device on acute kidney injury outcomes in the intensive care unit: a multicenter pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8142241" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Continuous arterial-venous diahemofiltration and continuous veno-venous diahemofiltration in infants and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9113935" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Continuous hemofiltration in the treatment of acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9113935" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Continuous hemofiltration in the treatment of acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7853885" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Renal replacement therapy after repair of congenital heart disease in children. A comparison of hemofiltration and peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8161723" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : A comparison of metabolic control by continuous and intermittent therapies in acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15909592" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Estimating the impact of renal replacement therapy choice on outcome in severe acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23471476" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : High-dose continuous renal replacement therapy for neonatal hyperammonemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24122260" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A biphasic dialytic strategy for the treatment of neonatal hyperammonemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15730613" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Hyperosmolar solutions in continuous renal replacement therapy for hyperosmolar acute renal failure: a preliminary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27896442" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Regional citrate anticoagulation for continuous renal replacement therapy in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27427878" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Circuit Lifetime With Citrate Versus Heparin in Pediatric Continuous Venovenous Hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15855212" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Multi-centre evaluation of anticoagulation in patients receiving continuous renal replacement therapy (CRRT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23102589" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Continuous renal replacement therapy for children≤10 kg: a report from the prospective pediatric continuous renal replacement therapy registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31462396" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Kidney Support in Children using an Ultrafiltration Device: A Multicenter, Retrospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24856026" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Continuous renal replacement therapy in neonates and small infants: development and first-in-human use of a miniaturised machine (CARPEDIEM).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32440948" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Continuous kidney replacement therapy in critically ill neonates and infants: a retrospective analysis of clinical results with a dedicated device.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27139897" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : CVVHD treatment with CARPEDIEM: small solute clearance at different blood and dialysate flows with three different surface area filter configurations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31608591" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Efficacy and safety of prolonged daily hemodialysis in critically ill children weighing less than 10 kg.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29315136" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Renal Replacement Therapy in the Critically Ill Child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11793102" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Pediatric acute renal failure: outcome by modality and disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22839207" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Permissive hypofiltration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699489" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Demographic characteristics of pediatric continuous renal replacement therapy: a report of the prospective pediatric continuous renal replacement therapy registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15696448" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Pediatric ARF epidemiology at a tertiary care center from 1999 to 2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28157807" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Factors Associated With Mortality in Continuous Renal Replacement Therapy for Pediatric Patients With Acute Kidney Injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18228045" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Continuous renal replacement therapy (CRRT) after stem cell transplantation. A report from the prospective pediatric CRRT Registry Group.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
